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Thiazolidinediones 
and renoprotection
The mechanism of renal ﬁbrosis 
in diabetic nephropathy with type 
2 diabetes remains a critical issue 
in renal research. It is known that 
hyperinsulinemia might be somehow 
responsible. As they report in this issue, 
Ohtomo et al. treated hypertensive 
obese type 2 diabetic rats with either 
insulin or a thiazolidinedione, 
pioglitazone (PGZ). While PGZ 
aggravated obesity and was less eﬀective 
in controlling glycemia, surprisingly, 
it improved renal function. PGZ also 
reduced proteinuria and demonstrated 
less histological evidence of diabetic 
glomerular and tubulointerstitial 
lesions. Both therapies reduced 
markers of oxidative stress, but only 
PGZ suppressed transforming growth 
factor-α (TGF-α) expression. Cultured 
kidney epithelial cells treated with 
insulin resulted in enhanced expression 
of TGF-α. A number of studies show 
that PGZ provides renoprotection in 
obese patients with type 2 diabetes and 
nephropathy. The mechanistic insight of 
this study is that hyperinsulinemia itself 
might be the culprit in renal ﬁbrosis. 
See page 1512.
β-blockers improve 
mortality in renal 
patients undergoing 
vascular surgery
The protective eﬀects of β-blockers in 
heart failure and after cardiovascular 
surgery are now well known. Yet 
patients with chronic kidney disease 
have excess cardiovascular mortality. 
Hence, Welten et al. studied the 
eﬀects of β-blockers in a large cohort 
of vascular surgery patients, some 
of whom had kidney disease. All 
patients received follow-up for 14 
years. Patients with advanced kidney 
disease had a higher mortality at 
both short- and long-term follow-
ups. Remarkably, treatment with 
β-blockers was signiﬁcantly associated 
with a lower risk of mortality after 
surgery. Although it is well known 
that patients undergoing vascular 
surgery have signiﬁcant mortality 
beneﬁts, identiﬁcation of similar 
beneﬁts in patients with kidney 
disease is an important ﬁnding in renal 
therapeutics. See page 1527.
Cationized catalase in 
cisplatin toxicity
Nephrotoxicity is a common side eﬀect 
of cisplatin treatment, even when 
it is used in recommended doses. 
The mechanism of nephrotoxicity 
is thought to be induction of toxic 
reactive oxygen species. Because 
catalase can hydrolyze peroxides, 
Ma et al. developed a strategy for 
intrarenal delivery of the enzyme 
producing cationized catalase. 
They showed that, unlike the 
native enzyme, cationized protein 
accumulated in the kidney on 
infusion into animals. When cisplatin 
was used to produce acute kidney 
injury, repeated intravenous doses 
of cationized catalase significantly 
decreased rises in creatinine, blood 
urea nitrogen, and evidence of renal 
tubular necrosis. In addition, markers 
of oxidative stress such as nitrite/
nitrate levels, lactic dehydrogenase 
activity, and renal total glutathione 
and malondialdehyde contents were 
also reduced. When cisplatin was 
administered to tumor-bearing 
animals in repeated doses of catalase, 
especially cationized catalase, it 
significantly increased the survival of 
cisplatin-treated tumor-bearing mice 
and prevented cisplatin-induced acute 
death. These important preclinical 
studies suggest a new avenue of 
therapy for treating cisplatin-related 
nephrotoxicity. See page 1535.
